ALXN2030

DRUG3 trials

Sponsors

Alexion Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc.

Conditions

AMRAntibody-Mediated RejectionAntibody-Mediated Rejection after Kidney TransplantationBiopsy-proven Histologic ScoresHealthyKidney Transplantation

Phase 1

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants

Active, not recruitingNCT05501717

Alexion Pharmaceuticals, Inc.Healthy

Start: 2022-08-16End: 2026-10-14Updated: 2026-04-09

Phase 2

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Active, not recruitingNCT06744647

Alexion Pharmaceuticals, Inc.AMR, Antibody-Mediated Rejection, Biopsy-proven Histologic Scores +1

Start: 2025-03-07End: 2028-11-07Updated: 2026-08-11

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients with Antibody-Mediated Rejection after Kidney Transplantation

Not yet recruitingCTIS2024-517498-25-00

Alexion Pharmaceuticals Inc.Antibody-Mediated Rejection after Kidney Transplantation

Target: 6Updated: 2025-12-05